Next 10 |
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, May 1, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discu...
2024-04-23 10:29:06 ET More on Edgewise Therapeutics Edgewise Therapeutics: Behind The Massive Rally Krystal Biotech, Candel, Edgewise gain after FDA fast track tags Seeking Alpha’s Quant Rating on Edgewise Therapeutics Historical earnings data for Edg...
2024-04-16 12:22:50 ET More on rare disease pharmas/biotechs Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy Sarepta Therapeutics: Another 'Hold' Call Ahead Of Some Key Catalysts Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success...
2024-04-11 02:27:54 ET Summary Sarepta Therapeutics reported strong Q4/2023 performance, with $365.1M in net product revenue, up 55% from the previous year. ELEVIDYS, despite not meeting its primary endpoint in the Phase III trial, showed significant improvements in motor function...
2024-04-08 16:11:05 ET Summary Sarepta Therapeutics generated $1.14 billion in revenues in 2023 from its four approved therapies for Duchenne Muscular Dystrophy. The company's gene therapy drug Elevidys faced concerns after a failed confirmatory study, causing a sharp market sell-...
2024-04-06 08:45:00 ET The biotech industry can be attractive for several reasons. Many leading biotechs develop innovative, life-saving therapies, a business that will only be phased out once we find an all-purpose cure for all illnesses. Further, biotechs often deliver better-than-average...
2024-04-01 10:17:11 ET More on Solid Biosciences Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid William Blair starts Solid Biosciences at outperform Piper Sandler upgrades Solid Biosciences to overweight Seeking Alpha’s Quant ...
2024-03-28 13:46:05 ET More on Invesco S&P 500 Equal Weight ETF: RSP: Equal Weighting The S&P 500 To Minimize Magnificent Seven Exposure Is Not Optimal RSP: I Firmly Believe In An Allocation To Equal-Weight At This Juncture RSP: Happy 2024! Don't Make Decisio...
2024-03-20 12:11:15 ET More on Kyowa Kirin Kyowa buyout Orchard wins FDA nod for rare disease therapy Historical earnings data for Kyowa Kirin Dividend scorecard for Kyowa Kirin Financial information for Kyowa Kirin Read the full article on Seeking ...
2024-03-19 10:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, May 1, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discu...
2024-04-06 08:45:00 ET The biotech industry can be attractive for several reasons. Many leading biotechs develop innovative, life-saving therapies, a business that will only be phased out once we find an all-purpose cure for all illnesses. Further, biotechs often deliver better-than-average...
2024-03-19 10:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...